Aquinox Pharmaceuticals Inc. (AQXP) Research Coverage Started at Leerink Swann
Equities researchers at Leerink Swann initiated coverage on shares of Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) in a research note issued to investors on Tuesday. The brokerage set an “outperform” rating on the stock.
Several other research analysts have also weighed in on the stock. Jefferies Group upped their target price on shares of Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the stock a “hold” rating in a research report on Friday, August 5th. Canaccord Genuity set a $22.00 target price on shares of Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, July 21st. Finally, Zacks Investment Research lowered shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $19.86.
Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) opened at 14.52 on Tuesday. The stock’s market cap is $249.92 million. Aquinox Pharmaceuticals has a 52-week low of $6.01 and a 52-week high of $16.75. The stock’s 50 day moving average is $11.93 and its 200 day moving average is $9.03.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.22. On average, equities analysts expect that Aquinox Pharmaceuticals will post ($2.23) earnings per share for the current fiscal year.
In other Aquinox Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker purchased 2,783,605 shares of the stock in a transaction dated Tuesday, September 20th. The shares were acquired at an average cost of $12.25 per share, for a total transaction of $34,099,161.25. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.00% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in the stock. Bank of Montreal Can purchased a new position in shares of Aquinox Pharmaceuticals during the second quarter valued at about $166,000. BlackRock Inc. increased its position in shares of Aquinox Pharmaceuticals by 24.3% in the first quarter. BlackRock Inc. now owns 50,600 shares of the company’s stock valued at $446,000 after buying an additional 9,900 shares during the last quarter. Bridgeway Capital Management Inc. increased its position in shares of Aquinox Pharmaceuticals by 416.7% in the second quarter. Bridgeway Capital Management Inc. now owns 62,000 shares of the company’s stock valued at $410,000 after buying an additional 50,000 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Aquinox Pharmaceuticals by 21.8% in the first quarter. Geode Capital Management LLC now owns 62,949 shares of the company’s stock valued at $555,000 after buying an additional 11,268 shares during the last quarter. Finally, Royce & Associates LP increased its position in shares of Aquinox Pharmaceuticals by 416.4% in the first quarter. Royce & Associates LP now owns 96,167 shares of the company’s stock valued at $848,000 after buying an additional 77,545 shares during the last quarter. Institutional investors and hedge funds own 68.20% of the company’s stock.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.
Receive News & Stock Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.